Top ▲

Plasmodium cynomolgi

Species ID:107
Name:Plasmodium cynomolgi
Associated with:2 targets
7 ligands
Description
P. cynomolgi (Pc) is a malaria parasite that infects non-human primate species with the natural mammalian host being Asian Old World monkeys. Pc is used as a model for human P. vivax infection because these species are phylogenetically close and share a similar lifecycle, including the dormant liver form (hypnozoite).

Interactions

Interactions
Key to terms and symbols Click column headers to sort
Target Ligand Sp. Action Value Parameter Reference
Plasmodium falciparum phosphatidylinositol 4-kinase MMV048 Pc - 5.0 – 7.2 pIC50 3
pIC50 7.2 (IC50 6.1x10-8 M) P. cynomolgi assay to assess inhibition of liver stage development (prophylactic activity) [3]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
pIC50 7.2 (IC50 6.4x10-8 M) P. cynomolgi assay to assess inhibition of liver stage development (prophylactic activity) [3]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
pIC50 <5.0 (IC50 >1x10-5 M) P. cynomolgi assay to assess elimination of hypnozoites (potential as a radical cure) [3]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
Plasmodium falciparum phosphatidylinositol 4-kinase UCT943 Pc - >8.0 pIC50 1
pIC50 >8.0 (IC50 <1x10-8 M) P. cynomolgi assay to assess inhibition of liver stage development (prophylactic activity) [1]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
Plasmodium falciparum cytochrome b ELQ-300 Pc - ~7.0 pIC50 2
pIC50 ~7.0 (IC50 ~1x10-7 M) High-content fluorescence imaging to quantify the number of developing hepatic schizonts in primary rhesus hepatocytes infected with sporozoites from the M strain of P. cynomolgi [2]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
Unknown MOA tafenoquine Pc - - - 4
P. cynomolgi infected primary rhesus hepatocyte assay, 70-90% inhibition of hypnozoites at 10µM [4]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of schizonts at 10µM [4]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
Unknown MOA primaquine Pc - 6.1 – 6.4 pIC50 4
pIC50 6.4 (IC50 3.7x10-7 M) P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of schizonts at 10µM [4]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
pIC50 6.1 (IC50 8.4x10-7 M) P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of hypnozoites at 10µM [4]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
Unknown MOA NPC1161B Pc - - - 4
P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of schizonts at 10µM [4]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay
P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of hypnozoites at 10µM [4]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
Unknown MOA bulaquine Pc - - - 4
P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of hypnozoites at 10µM [4]
Lifecycle stages: Plasmodium dormant liver stage (hypnozoite)
Description: Parasite liver stage assay
P. cynomolgi infected primary rhesus hepatocyte assay, >90% inhibition of schizonts at 10µM [4]
Lifecycle stages: Plasmodium liver stage (sporozoite, hepatic schizont, hepatic merozoite)
Description: Parasite liver stage assay

References

Show »

1. Brunschwig C, Lawrence N, Taylor D, Abay E, Njoroge M, Basarab GS, Le Manach C, Paquet T, Cabrera DG, Nchinda AT et al.. (2018) UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrob Agents Chemother, 62 (9). [PMID:29941635]

2. Nilsen A, LaCrue AN, White KL, Forquer IP, Cross RM, Marfurt J, Mather MW, Delves MJ, Shackleford DM, Saenz FE et al.. (2013) Quinolone-3-diarylethers: a new class of antimalarial drug. Sci Transl Med, 5 (177): 177ra37. [PMID:23515079]

3. Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, Lee MCS, Basak R, Ghidelli-Disse S, Lafuente-Monasterio MJ et al.. (2017) Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med, 9 (387). [PMID:28446690]

4. Zeeman AM, van Amsterdam SM, McNamara CW, Voorberg-van der Wel A, Klooster EJ, van den Berg A, Remarque EJ, Plouffe DM, van Gemert GJ, Luty A et al.. (2014) KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother, 58 (3): 1586-95. [PMID:24366744]